Enhertu
Enhertu Approved for Unresectable or Metastatic HER2-positive Solid Tumors
The FDA granted accelerated approval to fam-trastuzumab Enhertu for adult patients with unresectable or metastatic ...
APRIL 10, 2024
Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan
Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...
JANUARY 13, 2023
Enhertu Approved as HER2-Directed Therapy for Certain Lung Cancer Patients
The FDA granted a new indication for trastuzumab deruxtecan-nxki (Enhertu, AstraZeneca/Daiichi Sankyo) to treat ...
AUGUST 15, 2022
FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas
The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with ...
JANUARY 31, 2021
Load more